Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia. 1993

H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

To maximize the thermal enhancement of antitumor effect and minimize normal tissue damage, the timing of Adriamycin (ADM) administration in relation to hyperthermia was examined. Tumor growth of a subcutaneously transplanted fibrosarcoma as well as damage in normal tissues were measured in F344 rats treated with variable schedules of ADM and hyperthermia. Simultaneous application of 5 mg/kg i.v. of ADM with hyperthermia (120 min at 41.5 degrees C) resulted in a synergistic antitumor effect, but there was no thermal enhancement of the antitumor activity when 2.5 mg/kg ADM was given. Thermal enhancement of the antitumor effect induced by 5.0 mg/kg ADM was greater when ADM was given 30 min before or just prior to hyperthermia compared to that given during hyperthermia. ADM given prior to hyperthermia caused less damage to normal tissue than that given during hyperthermia, as evidenced by a prolonged survival and lower incidence of ascites and tendency to bleed. Thus ADM administration 30 min before or just prior to hyperthermia resulted in greater therapeutic gains than ADM given during hyperthermia. In the light of these results, the optimal scheduling of administration of ADM with hyperthermia is important for a therapeutic gain for cancer patients.

UI MeSH Term Description Entries
D006979 Hyperthermia, Induced Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs. Fever Therapy,Hyperthermia, Local,Hyperthermia, Therapeutic,Thermotherapy,Induced Hyperthermia,Therapeutic Hyperthermia,Therapy, Fever,Local Hyperthermia
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
December 1989, Cancer research,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
November 1983, Nihon Sanka Fujinka Gakkai zasshi,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
October 1984, Cancer research,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
June 2011, Zhongguo shi yan xue ye xue za zhi,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
December 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
September 2007, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
October 2001, International journal of molecular medicine,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
July 1991, Cancer research,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
February 1986, Japanese journal of cancer research : Gann,
H Baba, and Y Maehara, and H Takeuchi, and S Inutsuka, and K Sugimachi
August 1983, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!